Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice

AstraZeneca

Status: Completed

Conditions: S. Aureus Bloodstream Infection

Study type: Observational

Funder types: Industry

Identifiers

NCT01212601

NIS-ICN-DUM-2010/1

Details and patient eligibility

About

This is a Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN treatment under condition of actual usage in clinical practice.

Full description

MC MD

Enrollment: 203 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient has received CUBICIN treatment, decided by treating physician
• A patient who is considered as ethnic Chinese
• Provision of subject informed consent

Exclusion criteria

• A patient record will not be eligible for the registry database if the patient received CUBICIN as part of a controlled clinical study for the current infection episode.

Trial design

203 participants in 1 patient group

1